TECH
HealthcareBio-Techne Corporation · Biotechnology · $8B
What is Bio-Techne Corporation?
Bio-Techne Corporation is a Minneapolis-based life science company that develops and sells reagents, instruments, and diagnostic tools for research and clinical markets worldwide.
Bio-Techne operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment supplies biological reagents — including cytokines, antibodies, and cell selection tools — alongside automated protein analysis instruments. The Diagnostics and Genomics segment provides diagnostic assays, molecular controls, spatial genomics tools, and oncology kits for both research and regulated clinical use.
Founded in 1989 and headquartered in Minneapolis, Minnesota.
- Cytokines, growth factors, and antibody reagents
- Automated western blot and multiplexed ELISA instruments
- Spatial genomic and tissue-based in-situ hybridization assays
- Oncology and genetic carrier screening diagnostic kits
Is TECH a Good Stock to Buy?
UQS Score rates TECH as Below Average overall.
The Risk pillar stands out as the clearest positive, suggesting Bio-Techne carries relatively manageable financial and operational risk compared to many peers. Valuation lands at Neutral, meaning the stock is neither obviously cheap nor stretched by UQS criteria.
Both the Quality and Growth pillars are rated Weak, pointing to meaningful headwinds in profitability trends and business expansion. The Moat pillar is Neutral, indicating no decisive competitive edge is currently reflected in the score.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does TECH pay dividends?
Yes — Bio-Techne Corporation pays a dividend.
Bio-Techne pays a regular dividend, which is relatively uncommon among mid-cap life science companies. This signals a degree of financial stability, though investors should weigh the dividend against the Weak Quality and Growth pillar ratings when assessing total return potential.
When does TECH report earnings?
Bio-Techne reports earnings on a quarterly cadence, typical for US-listed equities.
The Weak Growth pillar suggests recent revenue and earnings trends have lagged expectations relative to sector peers. Investors tracking near-term results should monitor whether the Diagnostics and Genomics segment can offset softness elsewhere.
For the most recent quarter's results, visit Bio-Techne's investor relations page directly.
TECH Price History
-41.1% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Bio-Techne Corporation?
Based on Bio-Techne Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Bio-Techne do?
Bio-Techne develops and manufactures life science reagents, instruments, and diagnostic products. Its two segments — Protein Sciences and Diagnostics and Genomics — serve academic researchers, biopharma companies, and clinical diagnostic labs worldwide.
Does TECH pay dividends?
Yes, Bio-Techne pays a regular dividend. This is notable for a mid-cap life science company. Investors should review current dividend details on the company's investor relations page, as amounts can change.
When does TECH report earnings?
Bio-Techne reports on a standard quarterly schedule. For confirmed upcoming earnings dates, check the company's investor relations page or your brokerage platform, as our data source does not cover specific future dates.
Is TECH a good stock to buy?
UQS Score rates TECH as Below Average, driven by Weak Quality and Growth pillars. The Strong Risk rating offers some reassurance, but the overall profile suggests caution. The full pillar breakdown is available to Pro members.
Is TECH overvalued?
The UQS Valuation pillar for TECH is rated Neutral, meaning the stock does not appear significantly overpriced or underpriced by UQS criteria. Context from the other pillars matters — view the complete analysis with a Pro account.
What is TECH's market cap bracket?
Bio-Techne is classified as a mid-cap company. This places it in a segment of the market that can offer growth potential but may carry more volatility than large- or mega-cap peers.
Is TECH a long-term quality investment?
As a long-term quality indicator, TECH's Below Average UQS Score — reflecting Weak Quality and Growth alongside a Neutral Moat — raises questions about durable compounding potential. The Strong Risk pillar is a relative positive worth monitoring over time.
What sector does TECH belong to?
Bio-Techne operates in the Healthcare sector, specifically within life science tools and diagnostics. This segment serves both research institutions and regulated clinical diagnostic markets globally.
Unlock Full TECH Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Moat, Growth, Risk, and Valuation
- ✓Access detailed financial metrics behind each pillar rating
- ✓Compare TECH against sector peers on a standardized scoring framework
- ✓Track score changes over time with Pro member history
Pro Analysis
TECH — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | 47.5 | 41.8 | 40.0 | 28.2 | 89.6 | 53.3 | +2.1 |
| May 7, 2026 | 45.4 | 34.4 | 40.0 | 31.0 | 82.6 | 54.5 | +0.7 |
| May 3, 2026 | 44.7 | 34.4 | 40.0 | 31.0 | 82.6 | 50.3 | -0.1 |
| Apr 26, 2026 | 44.8 | 34.4 | 40.0 | 31.0 | 82.6 | 50.7 | +0.4 |
| Apr 24, 2026 | 44.4 | 34.4 | 40.0 | 31.0 | 82.6 | 48.2 | 0.0 |
| Apr 19, 2026 | 44.4 | 34.4 | 40.0 | 31.1 | 82.6 | 48.2 | -0.2 |
| Apr 18, 2026 | 44.6 | 34.4 | 40.0 | 31.2 | 82.6 | 49.1 | -1.8 |
| Apr 14, 2026 | 46.4 | 34.4 | 40.0 | 31.2 | 82.6 | 61.3 | -0.2 |
| Apr 12, 2026 | 46.6 | 34.4 | 40.0 | 31.2 | 82.6 | 62.6 | -0.2 |
| Apr 10, 2026 | 46.8 | 34.4 | 40.0 | 31.2 | 82.6 | 64.1 | -0.1 |
TECH — Pillar Breakdown
Quality
— 41.8/100 (25%)Bio-Techne Corporation has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 28.2/100 (20%)Bio-Techne Corporation faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 89.6/100 (15%)Bio-Techne Corporation carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 53.4/100 (15%)Bio-Techne Corporation has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 40/100 (25%)Bio-Techne Corporation possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for TECH.
Score Composition
Financial Data
More Stock Analysis
How is the TECH UQS Score Calculated?
The UQS (Unified Quality Score) for Bio-Techne Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Bio-Techne Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Bio-Techne Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.